IR@PKUHSC  > 北京大学精神卫生研究所
学科主题精神卫生
Relapse prevention study of paliperidone eltended-release tablets in Chinese patients with schizophrenia
Rui, Qing1; Wang, Yang1; Liang, Shu2; Liu, Yanning1; Wu, Yue1; Wu, Qingqi1; Nuamah, Isaac3; Gopal, Srihari3
关键词Chinese Paliperidone Schizophrenia Symptoms Time To Relapse
刊名PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
2014-08-04
DOI10.1016/j.pnpbp.2014.02.007
53页:45-53
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Clinical Neurology ; Neurosciences ; Pharmacology & Pharmacy ; Psychiatry
研究领域[WOS]Neurosciences & Neurology ; Pharmacology & Pharmacy ; Psychiatry
关键词[WOS]OPEN-LABEL ; RISPERIDONE ; SAFETY ; HALOPERIDOL ; EFFICACY ; PLACEBO ; ARIPIPRAZOLE ; ER
英文摘要

Objectives: The objective of this study was to evaluate the long-term efficacy, safety, and tolerability of paliperidone extended-release (pali ER), in Chinese patients with schizophrenia.

Methods: In this parallel-group, relapse prevention, phase-3 study (screening [14-day], pali ER open-label run-in [8-week] and stabilization [6-week] phases, and double-blind (DB) treatment [variable duration], and open-label extension phases [24-week]), 136/201 patients with schizophrenia were randomized (1:1) to pall ER (3-12 mg) or placebo during the DB phase.

Results: Final analysis showed that, out of 135 patients in ITT (DB) population, 71(52.6%) had a relapse event, 45 (33.3%) were ongoing at the time the study was stopped, and 19(14.1%) discontinued from the DB phase. Time to relapse (primary endpoint) favored pali ER (hazard ratio = 5.23 [95% CI: 2.96, 9.25], p <0.0001). Rate of relapses (55/71 [77.5%] placebo; 16/64 [25%] pali ER) and secondary endpoints (change from baseline in Positive And Negative Syndrome Scale [PANSS] and Clinical Global Impression - Severity Scores) were significantly lower (p < 0.001) in pali ER group vs placebo, in favor of pali ER More psychiatric-related treatment-emergent adverse events (TEAEs) occurred in placebo- (21.1%) than pali ER group (10.9%). Most common (>3%) TEAEs in placebo group were insomnia and schizophrenia (8.5% each), while in pali ER group were aggression and akathisia (4.7% each), and schizophrenia, tremor, nausea, amenorrhea, and salivary hypersecretion (3.1% each). All serious TEAEs were psychiatric-related (schizophrenia, aggression, completed suicide, auditory hallucination, suicide attempt) and more frequent in placebo- (113%) versus pali ER group (3.1%). Death and tardive dyskinesia-related discontinuation (n = 1 each) occurred in placebo group. Body weight increase from run-in baseline was greater in pali ER group (mean increase: 3.90 kg) versus placebo (mean increase: 2.05 kg).

Conclusions: This study confirms the findings from earlier pali ER global relapse-prevention studies and demonstrates that pali ER treatment (3-12 mg) is efficacious over the long-term and significantly delays relapse in Chinese patients with schizophrenia. No new safety signals were detected in this population. (C) 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).

语种英语
WOS记录号WOS:000338813600006
资助机构Janssen Research &amp ; Development, LLC.
引用统计
被引频次:7[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/58059
专题北京大学精神卫生研究所
作者单位1.Janssen Res & Dev LLC, Titusville, NJ USA
2.Janssen Res & Dev, Beijing, Peoples R China
3.Peking Univ, Hosp 6, Beijing 100871, Peoples R China
推荐引用方式
GB/T 7714
Rui, Qing,Wang, Yang,Liang, Shu,et al. Relapse prevention study of paliperidone eltended-release tablets in Chinese patients with schizophrenia[J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY &amp; BIOLOGICAL PSYCHIATRY,2014,53:45-53.
APA Rui, Qing.,Wang, Yang.,Liang, Shu.,Liu, Yanning.,Wu, Yue.,...&Gopal, Srihari.(2014).Relapse prevention study of paliperidone eltended-release tablets in Chinese patients with schizophrenia.PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY,53,45-53.
MLA Rui, Qing,et al."Relapse prevention study of paliperidone eltended-release tablets in Chinese patients with schizophrenia".PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY 53(2014):45-53.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Rui, Qing]的文章
[Wang, Yang]的文章
[Liang, Shu]的文章
百度学术
百度学术中相似的文章
[Rui, Qing]的文章
[Wang, Yang]的文章
[Liang, Shu]的文章
必应学术
必应学术中相似的文章
[Rui, Qing]的文章
[Wang, Yang]的文章
[Liang, Shu]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。